TOM70 Antibody

What is TOM70 and what cellular functions does it perform?

TOM70 (Translocase of Outer Mitochondrial Membrane 70) is a 608-amino acid protein member of the Tom70 family with a calculated molecular weight of 67 kDa, although it typically appears at 70-75 kDa on Western blots . It serves as a critical receptor in the outer mitochondrial membrane that functions as a docking partner for cytosolic chaperone proteins, facilitating the uptake of newly synthesized chaperone-bound proteins during mitochondrial biogenesis .

Beyond its canonical role in protein import, TOM70 has emerged as a significant factor in disease pathways. It participates in recruiting PINK1 and Parkin to mitochondria—proteins that become activated following mitochondrial membrane depolarization to identify damaged mitochondria, suggesting a potential role in Parkinson's Disease pathogenesis . Recent research has also revealed that the Orf9b protein encoded by SARS-CoV-2 binds to TOM70, leading to suppression of interferon responses, implicating this protein in viral pathogenesis mechanisms .

What are the validated applications for TOM70 antibodies?

TOM70 antibodies have been validated across numerous experimental applications, allowing for comprehensive protein analysis. The following table summarizes the key applications with corresponding recommended dilutions:

It is important to note that while these dilutions serve as starting points, optimization for your specific experimental system is recommended .

What tissue and cell types show reliable TOM70 detection?

TOM70 antibodies have demonstrated consistent detection across multiple tissue and cell types, reflecting the ubiquitous nature of mitochondria. Western blot analysis has successfully detected TOM70 in MCF-7 cells, HeLa cells, rat heart and skeletal muscle tissues, as well as mouse heart, brain, and liver tissues . Immunohistochemistry applications have validated TOM70 detection in human heart, kidney, and liver tissues, as well as mouse heart tissue . For cellular immunofluorescence, reliable detection has been achieved in HepG2 cells .

When designing experiments, incorporating these validated cell and tissue types as positive controls can provide confidence in antibody performance, particularly when exploring TOM70 expression in novel contexts.

What are the recommended optimization strategies for TOM70 immunofluorescence?

Successful TOM70 immunofluorescence requires careful attention to fixation and permeabilization protocols, as mitochondrial proteins can be sensitive to processing conditions. For optimal results:

• Fixation: 3.7% paraformaldehyde fixation has been validated for TOM70 detection . Avoid over-fixation, which can mask epitopes.

• Permeabilization: Use 0.1-0.2% Triton X-100 for balanced permeabilization that maintains mitochondrial structure while allowing antibody access.

• Antibody dilution: Begin with a 1:200-1:800 dilution range for primary antibody incubation . For secondary detection, anti-rabbit Alexa Fluor 647 has been successfully employed .

• Controls: Include a mitochondrial marker (such as MitoTracker or TOMM20) for co-localization confirmation and validation of mitochondrial staining patterns.

• Signal amplification: For tissues with lower TOM70 expression, consider tyramide signal amplification systems to enhance detection sensitivity.

Researchers have reported clear mitochondrial staining patterns at 1:300 dilution, making this a good starting point for optimization .

What protocol modifications are recommended for TOM70 Western blotting?

TOM70 Western blotting requires specific considerations to achieve clear, specific detection of the 70-75 kDa band:

• Sample preparation: Total cell lysates from various tissues and cell lines have successfully detected TOM70. Human, mouse, and rat samples have all shown reactivity .

• Gel percentage: 15% acrylamide gels have been reported to provide good resolution for TOM70, which typically appears slightly below 75 kDa .

• Dilution optimization: Start with 1:1000 dilution for most applications, though the validated range extends from 1:1000-1:6000 .

• Blocking conditions: PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) has been validated as an effective storage buffer for antibodies used in Western blotting .

• Signal verification: TOM70 antibodies may detect some fainter non-specific bands in addition to the strong specific band at ~70-75 kDa. Validation using knockout/knockdown controls can help confirm specificity .

Researchers have reported that TOM70 antibodies used for co-immunoprecipitation to detect overexpressed Flag-tagged proteins interacting with TOM70 can identify a sharp single band at the expected molecular weight .

How should TOM70 immunohistochemistry protocols be optimized?

TOM70 immunohistochemistry requires specific antigen retrieval methods and careful protocol optimization:

• Antigen retrieval: Two validated methods are suggested:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Antibody dilution: Begin with 1:50 dilution for initial testing, with validated range of 1:20-1:200 .

• Detection systems: Both DAB (3,3'-diaminobenzidine) and AEC (3-amino-9-ethylcarbazole) chromogens have been successfully used with TOM70 antibodies.

• Positive controls: Human heart, kidney, and liver tissues have been validated as positive controls for TOM70 IHC applications .

• Background reduction: If background staining occurs, addition of 0.1-0.3% Triton X-100 to antibody diluent can improve signal-to-noise ratio.

Tissue-specific optimization is crucial, as antigen accessibility may vary between different tissue types due to differences in mitochondrial density and tissue architecture.

How can TOM70 antibodies be utilized to study its role in Parkinson's Disease mechanisms?

TOM70's involvement in recruiting PINK1 and Parkin to mitochondria positions it as a significant protein in Parkinson's Disease (PD) research. To effectively study this relationship:

• Experimental design: Employ dual immunofluorescence or co-immunoprecipitation to investigate TOM70 interactions with PINK1 and Parkin under both basal and stressed conditions.

• Cellular models: Utilize neuronal cell lines treated with mitochondrial uncouplers (CCCP/FCCP) to induce mitochondrial depolarization, triggering the PINK1/Parkin pathway.

• Tissue analysis: Compare TOM70 expression and localization in postmortem brain samples from PD patients versus controls using validated IHC protocols (1:20-1:200 dilution) .

• Mechanistic studies: Combine TOM70 antibodies with mitochondrial fractionation techniques to quantify protein distribution between cytosol and mitochondria during mitophagy induction.

• Genetic manipulation: In TOM70 knockdown/knockout models, assess PINK1/Parkin recruitment efficiency using the validated antibodies (1:1000-1:6000 for WB) .

This approach allows for comprehensive analysis of how TOM70 contributes to mitochondrial quality control mechanisms relevant to Parkinson's Disease pathogenesis.

What methodological considerations are important when investigating TOM70-SARS-CoV-2 interactions?

The interaction between SARS-CoV-2 Orf9b protein and TOM70 represents an important area of viral pathogenesis research. To effectively study this interaction:

• Co-immunoprecipitation: Use TOM70 antibodies for pull-down experiments in cells expressing Orf9b, followed by Western blotting (1:1000-1:6000 dilution) .

• Cellular systems: Both overexpression systems and infection models can be employed, with attention to timing of sample collection (typically 24-48 hours post-infection/transfection).

• Interferon response: Measure interferon signaling markers in the presence and absence of TOM70 to confirm the functional consequence of the interaction.

• Microscopy approaches: Use immunofluorescence (1:200-1:800 dilution) to visualize co-localization of TOM70 and Orf9b in cellular contexts .

• Structural studies: Combine antibody-based detection methods with structural biology approaches to map the precise interaction domains.

These methodological approaches can help elucidate how viral proteins target mitochondrial import machinery to potentially evade immune responses.

How can TOM70 antibodies be used to investigate mitochondrial biogenesis mechanisms?

TOM70's function as a receptor for chaperone-bound proteins makes it an excellent target for studying mitochondrial biogenesis:

• Pulse-chase experiments: Combine metabolic labeling with TOM70 immunoprecipitation (0.5-4.0 μg for 1.0-3.0 mg of protein) to track newly synthesized proteins imported into mitochondria .

• Chaperone interaction studies: Use co-immunoprecipitation to identify specific chaperone proteins interacting with TOM70 during various cellular conditions.

• Stress response: Monitor TOM70 expression and localization under conditions that induce mitochondrial biogenesis (exercise, caloric restriction, chemical inducers) using Western blotting (1:1000 dilution) .

• Tissue-specific analysis: Compare TOM70 expression across tissues with different metabolic demands (heart, skeletal muscle, brain, liver) using validated antibodies in appropriate dilutions for each application .

• Developmental studies: Track TOM70 expression during cellular differentiation or organism development to correlate with mitochondrial maturation processes.

These approaches can provide insights into how cells regulate mitochondrial protein import during normal physiology and in response to cellular stresses.

What are common sources of variability in TOM70 antibody experiments and how can they be addressed?

Experimental variability with TOM70 antibodies can arise from several sources:

• Epitope accessibility: TOM70's mitochondrial membrane localization can result in epitope masking. Solution: Optimize fixation and permeabilization conditions for each application.

• Antibody specificity: Some TOM70 antibodies may detect non-specific bands. Solution: Validate using positive controls (HeLa cells, MCF-7 cells, mouse heart tissue) and negative controls (knockdown/knockout samples) .

• Sample preparation: Mitochondrial proteins can be sensitive to degradation. Solution: Use fresh samples, include protease inhibitors, and maintain cold chain throughout processing.

• Subcellular fraction purity: Mitochondrial enrichment protocols may yield variable purity. Solution: Verify fractionation quality using markers for different cellular compartments alongside TOM70 detection.

• Fixation artifacts: Particularly in immunofluorescence, fixation can alter mitochondrial morphology. Solution: Compare different fixatives (e.g., paraformaldehyde at 3.7% has been validated) .

Maintaining consistent experimental conditions and incorporating appropriate controls at each step can significantly reduce variability in TOM70 antibody-based experiments.

How should researchers validate the specificity of TOM70 antibodies in their experimental system?

Comprehensive validation of TOM70 antibodies is essential for generating reliable data:

• Multiple detection methods: Cross-validate findings using different applications (e.g., compare WB results with IF/ICC) .

• Molecular weight verification: Confirm detection at the expected molecular weight of approximately 70-75 kDa .

• Knockdown/knockout controls: Use siRNA/shRNA against TOM70 or CRISPR/Cas9-generated knockout samples to confirm antibody specificity.

• Peptide competition: Pre-incubation of the antibody with immunizing peptide should abolish specific signal.

• Literature comparison: Compare your findings with published data on TOM70 expression patterns in similar systems.

• Multiple antibodies: When possible, use antibodies from different suppliers or those targeting different epitopes of TOM70 to confirm observations.

Proper validation not only ensures experimental rigor but also helps troubleshoot unexpected results when they arise.

What quality control metrics should be assessed for TOM70 antibody performance across different lots?

Maintaining experimental consistency requires careful quality control when working with different antibody lots:

• Western blot comparison: Perform side-by-side comparisons to assess:

  • Signal intensity at the correct molecular weight (70-75 kDa)

  • Presence/absence of non-specific bands

  • Signal-to-noise ratio across dilution ranges (1:1000-1:6000)

• Immunofluorescence pattern: Compare mitochondrial staining patterns and intensity at standard dilutions (1:200-1:800) .

• Standard sample: Maintain a standard positive control sample (e.g., HeLa cell lysate) for batch-to-batch comparison.

• Titration analysis: Generate dilution curves for each new lot to determine optimal working concentration.

• Documentation: Maintain detailed records of antibody performance metrics for longitudinal quality assessment.

These approaches allow for methodical evaluation of antibody consistency, facilitating reliable data generation across extended research projects.

How can TOM70 antibodies be utilized to investigate mitochondrial dynamics in neurodegenerative diseases?

Beyond Parkinson's Disease, TOM70 research extends to broader neurodegenerative contexts:

• Multi-label imaging: Combine TOM70 antibodies (1:200-1:800 for IF) with markers of mitochondrial fission/fusion to assess correlations between import machinery and mitochondrial dynamics .

• Brain region analysis: Compare TOM70 expression across vulnerable and resistant brain regions in neurodegenerative disease models using immunohistochemistry (1:20-1:200) .

• Temporal studies: Track TOM70 expression changes during disease progression using Western blotting (1:1000-1:6000) on longitudinal samples .

• Organoid models: Apply validated TOM70 antibody protocols to patient-derived brain organoids to study disease mechanisms in complex 3D tissues.

• Therapeutic modulation: Assess how therapeutic candidates affect TOM70 expression and function as a potential readout of mitochondrial health.

This approach can provide insights into how disruptions in mitochondrial protein import contribute to neurodegeneration beyond established pathways.

What considerations are important when studying TOM70 in mitochondrial dysfunction related to metabolic disorders?

TOM70's role in mitochondrial protein import makes it relevant to metabolic disease research:

• Tissue-specific analysis: Compare TOM70 expression across metabolically active tissues (liver, skeletal muscle, adipose tissue) in health and disease states using validated WB protocols (1:1000-1:6000) .

• Nutrient challenge: Assess TOM70 expression changes in response to high-fat feeding, fasting, or exercise using validated antibodies.

• Co-immunoprecipitation: Identify changes in TOM70's interactome under metabolic stress conditions (0.5-4.0 μg antibody for 1.0-3.0 mg protein) .

• Subcellular fractionation: Quantify TOM70 distribution between mitochondrial subpopulations in metabolic tissues.

• Human samples: Apply optimized IHC protocols (1:20-1:200) to patient biopsies to translate findings from model systems to human disease .

These methodological approaches can help establish connections between altered mitochondrial protein import and metabolic dysfunction in conditions like diabetes, obesity, and fatty liver disease.